Bli medlem
Bli medlem

Du är här


Xvivo Perfusion: Redeye: Xvivo Perfusion - Please hold

The third quarter of the year showed weaker-than-expected sales growth
for Xvivo Perfusion, failing to live up to our high set expectations.
We revise our estimates with lower sales growth in the near-term, but
with reimbursement codes for the EVLP procedure in hand and
progression in the research portfolio, our view of the company's
long-term potential remains intact.

Access the Research Update by Arvid Necander at:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. (


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.